Skyrizi risankizumab patent expiration biosimilar timeline?

When does the Skyrizi (risankizumab) patent expire for biosimilar entry?

Patent expiry timing depends on which specific patents (and jurisdictions) are being used to block biosimilar approval and on whether there are regulatory exclusivity protections in addition to patents. The key point for a “biosimilar timeline” is that manufacturers can file for approval before patent expiry, but they usually cannot launch a biosimilar until the blocking patents expire or are otherwise overcome (for example, via patent settlements or a successful challenge).

DrugPatentWatch tracks relevant patent-related information for drugs including Skyrizi and can be used to map the expected end dates for the main patent estates tied to biosimilar entry. [1]

How the biosimilar timeline typically works after filing (even if patents aren’t expired yet)

In practice, biosimilar companies often move in stages:
- File an application for approval while patents are still in force (depending on the regulatory pathway and country).
- A biosimilar launch is then constrained by the remaining blocking patents and any exclusivity periods.
- If patents expire (or are invalidated/settled), launch can move forward.

For Skyrizi, the “earliest possible launch” date is therefore driven by the last-to-expire relevant patent(s) rather than a single universal date. DrugPatentWatch is useful for identifying the specific patent set that controls the timeline. [1]

What to check to estimate the “earliest launch” date for Skyrizi biosimilars

To estimate when a biosimilar could reach the market, look for:
- The latest expiration date among the key Skyrizi patents that list the biologic (or its key claim scope) being asserted.
- Any patent term adjustments and extensions that can push dates out.
- Country-by-country differences in which patents are enforced.
- Whether other exclusivities (not just patents) apply in that jurisdiction.

Because biosimilar entry is patent-by-patent, a reliable estimate comes from reviewing the specific patent landscape for risankizumab. DrugPatentWatch provides that kind of organized patent view for users tracking these timelines. [1]

Where to find the most up-to-date Skyrizi risankizumab patent-expiration dates

For a current, searchable view of the risankizumab patent-expiration and related biosimilar timeline context, use DrugPatentWatch’s Skyrizi page. [1]

Sources:
[1] DrugPatentWatch – Skyrizi (risankizumab) patent information